T he positive value of continuous monitoring of patients cared for in intensive care units (ICUs) seems intuitively obvious but has not been extensively objectively evaluated. Oximetry in particular has been adopted as a standard for monitoring in this environment, with little supporting evidence as to its value or effectiveness. The fact that hypoxemia can be present with few clinical signs and can rapidly lead to devastating outcomes makes a caregiver's desire for oximetry in the ICU environment strong. The actual impact on caregivers and patients in the ICU from oximetry is not known, although several studies have suggested that the number of blood gas measurements obtained during weaning may be reduced with the use of oximetry (1, 2) . Even in the operating room, where continuous monitoring by pulse oximetry was first pioneered and is mandated for patients receiving general anesthesia, there is little objective evidence to suggest that this monitoring leads to improved patient outcome (3) (4) (5) . Despite the lack of objective support, clinicians enthusiastically choose to use pulse oximetry in caring for anesthetized patients (4) . The belief that the routine use of pulse oximetry improves patient safety has led to reduced malpractice premiums for anesthesiologists after adoption of this standard in the operating room and postanesthesia care unit (6 -9) . The effect of continuous pulse oximetry on patients cared for in other venues, such as the recovery room, the ICU, and the emergency department, is even less well documented (10, 11) .
Oximetry failures are common, even in the operating room where patients are not moving (12) . In the classic study by Moller et al. (4) , oximetry failed in 2.5% of the 10,312 patients randomized to be monitored in the operating room with oximetry. In the more seriously ill patients, the failure rate rose to 7.2%. These failures are even more common in the postanesthesia care unit (13) . Oximetry failure occurs outside of the operating room setting, and missed actual desaturation events because of this failure are more frequent in the ICU. In addition to the direct risk to the patient from a missed desaturation event, there is concern about monitoring failures generating false alarms that distract caregivers from other important tasks and require them to spend time attending to the monitor rather than caring for patients. Frequent false alarms desensitize caregiv-ers and lead clinicians to ignore alarms, even though they may reflect true, critical conditions (the "crying wolf" phenomenon (14, 15) .
Although there are many studies demonstrating the accuracy and precision of various oximeter technologies, few studies have looked at clinically important outcomes potentially influenced by use of this technology. One area that has been studied is the effect of oximetry on the frequency of arterial blood gas analysis. Pulse oximetry may reduce the number of arterial blood gas analyses if the accuracy of the device used is adequate (16) . The acceptance of the accuracy of the monitor data could decrease healthcare costs, facilitate weaning, and reduce confirmatory laboratory studies (17) .
Those studies that have addressed patient outcome related to oximetry are usually anecdotal case reports or uncontrolled observations (18) . With the advent of significantly improved oximetry technology leading to more reliable monitoring, we sought to evaluate the impact of this improvement on ICU care processes. Our hypothesis was that improved oximetry would result in a measurable difference in patient care outcome variables compared with conventional, less reliable oximetry. This improved oximetry could result in more rapid weaning from mechanical ventilation, earlier extubation, and reduced cost. Indirectly, care might also improve if more caregiver attention could be provided to the patient, rather than responding to false alarms and oximetry failures.
We decided to study patients after cardiac surgery from the time of ICU entry until after successful extubation. This patient population was selected because it is relatively homogeneous, often hypothermic, subject to vigorous patient movements (shivering), and is routinely monitored with pulse oximetry. We also noted that oximetry frequently fails under the clinical conditions of the study (19 -22) . We were most interested in patient care outcomes. We also collected data on the reliability of both oximeters to confirm our assumption that performance of the improved device was superior to our conventional pulse oximeter (CPO). Our experimental design allowed us to compare the reliability of both devices in the same patient as patients were to be monitored by both devices simultaneously. We collected many patient care outcome variables but did not inform the clinical staff that this was our primary objective. Bedside caregivers were only informed that we were testing a new pulse oximeter. In this sense, the experimental subjects were the caregivers, and they were blinded to the study hypotheses and the expected differences in oximeter performance. To be clinically relevant, we hoped to see a meaningful change in care, such as a significantly shorter time to extubation. Our primary hypothesis was that ventilator weaning would be hastened and time to extubation would be reduced if better oximeter data were presented to the bedside caregivers.
METHODS
We studied patient management after cardiac revascularization surgery in an ICU. Patients were monitored continuously with an innovative pulse oximeter (IPO) employing advanced signal extraction and processing technology from the Masimo Company (Masimo SET, Irvine, CA) and with a CPO, an Ohmeda 3740 (Datex-Ohmeda, Louisville, CO). The Masimo SET oximetry technology has been shown to provide more consistent monitoring in conditions of low perfusion and during patient movement when compared with conventional pulse oximetry (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) . In this innovative device, the signal detection process is based on the assumption that arterial blood is not the only absorptive substance in tissue that may generate a pulsatile optical signal. During motion, venous and other nonarterial tissues may demonstrate fluctuating light absorption. This nonarterial blood may be detected by conventional oximeters as if it was pulsating arterial blood. The moving nonarterial blood is averaged with the arterial blood during the calculation of SpO 2 . The Masimo SET technology includes a low noise optical probe patient sensor and uses a discrete saturation transformation algorithm (33) . The discrete saturation transformation uses the red and infrared absorption signals and an adaptive filter system to separately identify the energy present at each saturation in the range of 0% to 100%. When the discrete saturation transformation identifies significant energy at a specific oxygen saturation, this means that there is a light-absorbing substance moving within the tissue that has that saturation. When the patient is not moving, this substance will be the pulsating arterial blood. During motion, the moving substance may be arterial, venous, or other moving blood that is being detected. Once the discrete saturation transformation identifies and verifies the energy peak produced by the pulsating arterial blood, usually this is the peak corresponding to the highest saturation in the discrete saturation transformation, it reports this value as the patient's SpO 2 . Thus, the Masimo oximeter is able to cancel the noise signal and separate the arterial signals from artifacts. This results in more reliable signal acquisition and reduces the risk of false alarms.
Both devices were attached to each study subject, each covered with an optical shield. The continuous data from each device was recorded on a laptop computer. Patients were prospectively randomized to have the output from one of the devices displayed for use by the bedside caregiver with the output from the other recorded but not displayed. Patients were informed of the purpose of the study (that we were testing a new oximeter), but written consent was deemed not required by the Human Investigation Committee of the University of Virginia because both devices are available commercially and approved for clinical use.
We estimated that it would take at least a 20% reduction in time to extubation to have a clinically significant impact on care. Power analysis with a 90% chance of detecting such a difference (assuming a SD of 25% or 30%) suggested a sample size of between 33 and 48 patients in each group. A total of 86 adult patients undergoing coronary artery revascularization surgery with good preoperative ventricular function (ejection fraction of Ͼ45%) were actually enrolled for the study. On arrival in the ICU, both a CPO and the IPO were attached to the same hand of each patient. The digits to which the monitors were attached were randomly chosen and could be moved as needed by the bedside clinician. The two devices, however, were always to remain on the same hand. The sensors from the two devices were optically shielded to eliminate interference from each other. The output from each device was simultaneously, continuously recorded on a laptop computer system until 4 hrs after extubation.
There were two monitoring and data collection stations, which could be moved to the patient's bedside, one designed to display only the CPO data to the clinician and the other designed to display only the IPO data. The first eligible patient on a study day was randomly assigned to one of the monitoring setups. The next eligible patient received the other setup. No more than two patients were studied at any one time, and this alternating pattern was continued for all cases. The study setups were identical except that each was designed to display only one of the oximeter outputs to the caregivers, with data from the other device collected but not displayed. Clinicians could not change the setup to gain access to the data from the blinded device. No other clinical management processes or protocols were altered during the study.
Pulse oximetry "failure percentage" was used as a measure of the efficiency of monitoring. Failure percentage was defined as the percentage of total monitoring time when the monitor output was unreliable, either reading zero saturation, no signal, or obvious artifact or when a coincident arterial blood gas calculated saturation demonstrated a Ͼ10% absolute difference in saturation. If the two oximeters displayed discordance by Ͼ5% in absolute saturation, the continuous red and infrared signal that was recorded from the IPO was used to calculate the instantaneous saturation. A conventional spectral method can be used on non-motion-affected segments to calculate the saturation from this raw data. The oximeter producing this calculated actual saturation value was then assumed to be correct, and the other was considered incorrect. This "error time" was added to the failure time to determine a total failure time. Episodes of failure time or error time of Ͻ1 min of duration were ignored. We determined each monitor's failure time, the time of weaning to an FIO 2 of 0.4, time to extubation, number of ventilator changes during weaning to an FIO 2 of 0.4 and extubation, and the number of arterial blood gas measurements obtained during weaning to FIO 2 of 0.4 and extubation. From the clinically initiated arterial blood gas determinations, the bias and precision of both devices were calculated using the method of Bland and Altman (34) . Clinicians were only told that we were assessing the accuracy of the pulse oximeter devices.
Oximeter reliability was compared by using the failure percentage for each device. The failure time in total minutes was determined from the computerized recording, and the failure percentage was calculated by dividing the failure time by the total monitored time. Comparison of clinical outcome variables was made between patients grouped by the specified oximeter when used "unblinded." Significance of differences was determined by using paired and unpaired t-tests, as appropriate. Significance was judged at the p Ͻ .05 level.
RESULTS
A total of 86 patients were entered into the study during a 13-month period from August 1999 through September 2000. For practical reasons, this included approximately 100 potential study days when the investigators were available to initiate the monitoring process. There were 410 patients admitted to the ICU after elective coronary artery bypass surgery on the study days. On 28 study days, only one case was available to study; by protocol, half of these were randomized to each study group. On 54 days, the first and second admitted patients were both studied, half of the first cases were randomized to each oximeter. On four study days, the first case was not entered into the study, primarily because of a different eligible patient arriving first in the unit unexpectedly. One studied patient was a fifth case; this was because the oximeter setup was released late in the day after being used on another study patient from the previous day. The average age and sex distribution of the eligible patients not entered into the study was identical to those that were studied.
Three patients had inadequate clinical data collected (including hospital number) to permit analysis of the clinical outcome variables, and all were randomized to the CPO group. One patient assigned to the IPO was never weaned to an FIO 2 of 0.4 or extubated during the study protocol and was excluded from analysis. A total of 82 patients were available for analysis of clinical management, 43 in the IPO group and 39 in the CPO group. There were 66 men and 16 women studied; 36 men and seven women in the IPO group and 30 men and nine women in the CPO group (chi-square, p ϭ .438). The average age was 63.5 Ϯ 11.2 yrs. Four patients, all in the CPO group, were never weaned to 40%, but they were extubated from a higher FIO 2 ; these patients were included in the analysis.
There was no difference in the time to extubation between the two groups. However, patients managed with the IPO device were weaned to an FIO 2 of 0.4 on an average of Ͼ1 hr sooner and with significantly fewer arterial blood gas analyses (Table 1) . If the four patients in the CPO group who had been extubated from an FIO 2 of Ͼ0.4 are excluded from the analysis, the significance of these differences remains unchanged.
Although all the patients who were entered into the study were managed with the designated experimental workstation, the unattended computer data collection system failed to collect all the data from both oximeters a number of times. If Ͼ50% of the data from one device was missing, the record was considered inadequate, and the patient was not included in the data "reliability" evaluation. This data loss was most often caused by the unrecognized removal of the blinded oximeter. Of the original 86 patients entered, only 59 patients (68%) had adequate records. Adequate records were available for 30 patients in the IPO group (68% of those randomized to the IPO) and 29 patients in the CPO group (69% of those randomized to CPO). These records were analyzed for failure time by an investigator who was unaware of which oximeter was being used for clinical care. The reliability of the data collected by the two oximeters, when used both blinded and unblinded, is shown in Table 2 . Patients were monitored for an average of about 15 hrs (894.8 Ϯ 417.9 mins). The shortest monitoring period was 4 hrs and 20 mins, and the longest was 43 hrs and 40 mins. Overall, the CPO device experienced almost eight times more failure time than the IPO device; this difference was highly significant. When comparing the performance of each device with itself during blinded (unattended) and unblinded (clinically available) use, there was a tendency to less failure time in both oximeters in the unblinded condition; however, these differences did not reach the level of significance (IPO, p ϭ .148; CPO, p ϭ .235). When the failure percentage of the unblinded CPO was compared with the blinded IPO (the worst case scenario), the superiority of the IPO fell just short of Results of all available blood gas measurements were compared with the computerized record of oximetry data to determine the accuracy of the two oximeters for tracking oxygenation status. There were a total of 283 blood gas measurements available for this analysis; 134 blood gas measurements were obtained while the IPO was unblinded, and 149 were obtained while the CPO was unblinded. The bias (mean Ϯ SD) was calculated, as the difference between the SpO 2 and the average of the SpO 2 and SaO 2 , for each oximeter, independent of blinding condition for all blood gas samples obtained (Table 3) . Because of the large range of the bias for the CPO oximeter, the calculation was repeated using only the blood gas data obtained when the oximeter was used unblinded. However, the bias was not significantly improved by this grouping. The frequency distribution of the bias was counted for each oximeter and the CPO had a greater number of biases of Ͼ5%, as shown in the histogram in Figure 1 .
DISCUSSION
As we expected, the Masimo SET oximetry technology was more reliable and accurate than our conventional pulse oximetry in patients after cardiac surgery. Its use also resulted in far less monitoring failure time than conventional oximetry, as this new technology has been shown to perform well in poor perfusion states and during motion (35, 36) . This improved reliability occurred whether the device was being used as the clinical monitor or in the blinded (unattended) condition. Most importantly, clinicians chose to trust the monitored data and weaned patients from high FIO 2 more rapidly. They also reduced the number of confirmatory arterial blood gas measurements that were drawn when the data from the IPO device was clinically available. Extubation time, however, was not different between the two groups. We probably should not have been surprised by this finding because although weaning from high FIO 2 was accelerated by having data from the IPO, extubation is a complex decision involving factors other than oxygenation (e.g., PaCO 2 , temperature, level of consciousness, available personnel). Also, the SD in time to extubation was much greater than we anticipated (Ͼ50%), so it would take a very large number of patients to demonstrate a clinically important difference.
The potential impacts on patient care and safety of improved monitor function are several. Monitors providing false alarms distract caregivers from other tasks and require attention to troubleshoot or fix the monitor. This decreases efficiency, increases costs, and increases the likelihood that monitoring will not be continued because of caregiver distrust of the device. Ultimately, patient safety may be adversely affected. This is particularly important because oximetry is being used outside the ICU on the general ward where the effects of false alarms and missed true desaturations are even more likely to negatively affect patient outcome (37) (38) (39) .
During the time a monitor fails to provide any data but signals no alarm, the patient is not only not being monitored but the caregiver may have the false sense of security that all is well when the patient may be in grave danger. Recent studies on human error and patient safety point to caregiver cognitive overload and distraction (termed latent conditions) as one cause of patient injury or error. The Masimo SET pulse oximeter used in this study reduces the number of untrustworthy alarms and indicators. This performance benefit existed regardless of blinding, implying the potential for improved monitor reliability in unattended settings. These issues together have additional important positive effects on caregivers and patient outcome.
Presenting more reliable oximetry data to clinicians resulted in more rapid Figure 1 . Distribution of measurements with biases of Ͼ5% reported from each of the oximeters, blinded and unblinded, using the entire blood gas data set. and efficient weaning of the FIO 2 , with fewer arterial blood gas measurements. This is all the more remarkable because clinicians were unaware of this arm of the study, and they had no independent knowledge of the improved reliability or accuracy of the IPO device. Although we have not considered all variables that may have affected speed of weaning, it seems likely that when presented with more reliable monitoring information, caregivers quickly learn to trust the data and require less independent confirmatory measurements (i.e., arterial blood gas measurement). Because there were no differences in the number of ventilator changes made during weaning from a high FIO 2 , this supports the assumption that the same weaning approach was being employed in both groups. Our study has several weaknesses. It was not possible to blind clinicians to which oximeter was actually providing the displayed data. We do not believe this materially affected the outcome because no randomization violations occurred and clinicians could not gain access to the other device's data. However, clinician preference for the IPO device became apparent during the study. When a difficult or critically ill, unstable patient was in the ICU but not being studied, caregivers would seek out the IPO workstation (if it was not being used) and place it on this patient rather than use CPO, which is available at every bedside. This confirms clinician preference for the IPO technology and clinician belief of its positive impact on patient care.
Another weakness of our experiment is the loss of oximetry data in Ͼ30% of the patients studied. This was almost always because of the unrecognized patient removal of the blinded device. We did not have a dedicated research assistant overseeing the experimental subjects. We used clinical personnel to manage the experiment. Because the distribution of this data loss was random and equal in both groups, we do not believe it affected the analysis. Also, these data were only used to confirm the more consistent and reliable function of the IPO compared with the CPO device. More than 90% of the clinical data were collected, and this forms the heart of our study.
Another potential criticism of this study is that no "gold standard" was used to confirm the accuracy of the saturation measurements displayed by the monitors. Although the accuracy of the oximetry data may be important, this study was designed to evaluate the impact of reliability and not specifically accuracy (although accuracy is a part of reliability) on the process of care. Other studies have suggested that accuracy of various oximeters may be different. The bias calculations confirm that the IPO device more accurately tracked the PaO 2 (which was used to calculate the SaO 2 by using standard formulas). Except in the extreme, when any of the devices are able to display data, the displayed data are usually reasonably accurate. More important in the real world is the directional accuracy of trends. Because there were fewer interruptions in the data, the IPO may have been more consistent at demonstrating trends. It is this trend identification that caregivers need to trust a monitor. More reliable trend information may be the reason that caregivers seem to trust in the IPO device data.
We used the Masimo SET device as our improved technology for comparison. It is possible that other newer devices, which employ artifact rejection algorithms, would also positively affect ICU care. Many of these devices have been compared for performance in perfusion and motion stress tests. Most of these studies look only at carefully controlled, contrived experimental models and focus on accuracy of data. We would suggest that random use in the clinical situation would be the appropriate way to confirm clinical superiority. If there is a meaningful difference, head-to-head comparisons during simultaneous patient use will allow clinicians to identify the superior device. Clinician preference demonstrated during a randomized-use trial may be a better way to test new monitoring devices than bench evaluations of accuracy and performance. 
